Therapeutic inhibition of Mcl-1 blocks cell survival in estrogen receptor-positive breast cancers.

Williams, Michelle M; Elion, David L; Rahman, Bushra; Hicks, Donna J; Sanchez, Violeta; Cook, Rebecca S

Williams, Michelle M; Elion, David L; Rahman, Bushra; Hicks, Donna J; Sanchez, Violeta; Cook, Rebecca S.

Afiliação

Williams MM; Program in Cancer Biology, Vanderbilt University, Nashville, TN 37232, USA.
Elion DL; Program in Cancer Biology, Vanderbilt University, Nashville, TN 37232, USA.
Rahman B; Department of Cell and Developmental Biology, Vanderbilt University, Nashville, TN 37232, USA.
Hicks DJ; Department of Cell and Developmental Biology, Vanderbilt University, Nashville, TN 37232, USA.
Sanchez V; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Cook RS; Program in Cancer Biology, Vanderbilt University, Nashville, TN 37232, USA.

Oncotarget ; 10(52): 5389-5402, 2019 Sep 10.

Article em En | MEDLINE | ID: mdl-31595181

Palavras-chave

ABT-263 resistance; Mcl-1; luminal breast cancers; mTORC1 signaling

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Problema de saúde: 6_breast_cancer Idioma: En Revista: Oncotarget Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google